# SPECIALTY GUIDELINE MANAGEMENT

## **JETREA** (ocriplasmin intravitreal injection)

#### **POLICY**

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### **FDA-Approved Indication**

Jetrea is indicated for the treatment of symptomatic vitreomacular adhesion.

All other indications are considered experimental/investigational and not medically necessary.

### **II. CRITERIA FOR INITIAL APPROVAL**

#### Vitreomacular adhesion

Authorization of 90 days for a single dose (for each eye) may be granted for treatment of symptomatic vitreomacular adhesion.

#### III. REFERENCES

1. Jetrea [package insert]. Iselin, NJ: ThromboGenics, Inc; February 2017.

Jetrea 3000-A SGM P2021.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2021 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of